Safety and efficacy of hematopoietic stem cells mobilization in patients with multiple sclerosis

Hematology
Sławomira Kyrcz-KrzemieńMałgorzata Krawczyk-Kuliś

Abstract

Multiple sclerosis (MS) is a T-cell-mediated chronic inflammatory disorder of the central nervous system. Several agents have been approved for the treatment of MS; however, their efficacy is limited and short term. Autologous hematopoietic stem cell (HSC) transplantation may remain an encouraging option for some MS patients who failed prior conventional treatment. Objective To assess the safety and effectiveness of HSCs mobilization in patients with MS. Thirty-nine patients (20 females and 19 males) with relapsing-remitting MS at median age of 40 years (range: 25-63) were included in this study. As a stem cell mobilization, they received either granulocyte colony-stimulating factor (G-CSF) alone (10 µg/kg s.c. daily; n = 1) or cyclophosphamide (CY; 2.0 g/m(2) i.v. on days 1-2) followed by G-CSF (n = 38). The median number of mobilized HSCs per kg was 6.32 × 10(6) (range: 2.64-26.3 × 10(6)). One apheresis was sufficient for collection of HSCs in 30 out of 39 MS patients (77%). Two aphereses were required for seven patients, three for one and four for one (17, 3, and 3%; respectively). Side effects of HSCs mobilization have been reported for eight patients (30%) and they were following: Staphylococcus epidermidis bacteremia (n =...Continue Reading

References

Apr 1, 1997·Journal of Hematotherapy·H E Johnsen
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S L GoldbergK F Mangan
Sep 28, 2000·The New England Journal of Medicine·J H NoseworthyB G Weinshenker
Nov 9, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·H OpenshawS Forman
Aug 11, 2001·Bone Marrow Transplantation·R K BurtP A McSweeney
Aug 11, 2004·Best Practice & Research. Clinical Haematology·Dirk W van Bekkum
Jun 21, 2008·Lancet Neurology·Gianluigi Mancardi, Riccardo Saccardi
Sep 30, 2009·Acta Neurologica Scandinavica·C Rogojan, J L Frederiksen
Aug 11, 2010·Bone Marrow Transplantation·H Atkins
Dec 25, 2010·Therapeutic Advances in Neurological Disorders·Amer Awad, Olaf Stüve
Mar 23, 2011·The Mount Sinai Journal of Medicine, New York·Joy Derwenskus
Oct 18, 2011·Bone Marrow Transplantation·J A SnowdenUNKNOWN Paediatric Diseases Working Party (PDWP)
Feb 21, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Joachim BurmanJan Fagius
Jul 20, 2014·Current Neurology and Neuroscience Reports·Marta RadaelliGianvito Martino

❮ Previous
Next ❯

Citations

Oct 19, 2019·Current Treatment Options in Neurology·Anastasie M Dunn-PirioRevere P Kinkel
Aug 17, 2018·BioMed Research International·Ankit TandonRajnish Kumar Chaturvedi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.